摘要
人源性肿瘤组织移植(Patient-derived human tumor xenograft,PDX)模型能很好的保持原代肿瘤的组织病理学、生长及转移特性,并在多次传代后仍然能够在较大程度上保留原代肿瘤的这些特性,与原始患者肿瘤密切相关,具有重要科研价值。肝癌PDX模型已用于患者的个性化药物筛选、药物疗效的评价、治疗方向的探索、肝癌的发生发展机制等,具有良好的应用前景。该文对肝癌PDX模型的方法、应用以及成瘤因素等方面进行综述。
Patient-derived human tumor xenograft(PDX)models can maintain the histopathological,growth and metastasis characteristics of primary tumors well,and can still retain these characteristics of primary tumors in large degreeafter multiple passages.It is closely related to the tumors of primary patients with great importance in scientific research.The hepatocellular carcinoma PDX models has been used in patients′individualized drug screening,evaluation of drug efficacy,exploration of treatment direction,occurrence and development mechanism of hepatocellular carcinoma,etc.It shows excellent application prospects.This article reviews the methods,applications and tumorigenic factors of hepatocellular carcinoma PDX model.
作者
刘世芳
李宜航
陈德力
苏晶
吕亚娜
丁璇
李光
孙晓波
LIU Shi-fang;LI Yi-hang;CHEN De-li;SU Jing;LYU Ya-na;DING Xuan;LI Guang;SUN Xiao-bo(Pharmacological Center of Yunnan Branch, Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences & Peking Union Medical College,Jinghong Yunnan 666100, China;Key Labof Dai and Southern Medicine of Xishuangbanna Dai Autonomous Prefecture, Jinghong Yunnan 666100, China;Phytochemical Center of Hainan Branch,Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences & Peking Union Medical College, Haikou570311, China;Pharmacology and Toxicology Center,Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100093, China)
出处
《中国药理学通报》
CAS
CSCD
北大核心
2020年第4期475-478,共4页
Chinese Pharmacological Bulletin
基金
中国医学科学院医学与健康科技创新工程经费(No 2016-I2M-1-012)
国家自然科学基金资助项目(No 81503289)
云南省基础研究面上项目(No 2016FB143)
云南省技术创新人才培养项目(No 2017HB097)。
关键词
PDX
肝癌
方法
应用
成瘤因素
研究进展
PDX
hepatocellular carcinoma
method
application
tumor factor
research progress
